NEJM This Week — September 10, 2026

Four high-yield items this week. The MAJESTY trial establishes obinutuzumab as the first potential labeled treatment for primary membranous nephropathy. An outbreak investigation linking N-methylaniline exposure to severe methemoglobinemia in maritime migrants is flagged for military medicine relevance. A comprehensive Multiple Myeloma treatment-decisions review and a teaching case on IgA vasculitis round out the must-reads.

NephrologyMAJESTY · RCTHigh yield · IM

Obinutuzumab or Tacrolimus in Primary Membranous Nephropathy

In adults with primary membranous nephropathy, does obinutuzumab vs tacrolimus improve complete remission?

Population: 142 adults with biopsy-confirmed primary membranous nephropathy, persistent nephrotic-range proteinuria despite supportive care, eGFR ≥40. Excluded recent calcineurin inhibitors, cyclophosphamide, or B-cell-depleting agents.
Intervention: Obinutuzumab 1000 mg IV on day 1 and weeks 2, 24, and 26 (glycoengineered type II anti-CD20).
Comparison: Oral tacrolimus 0.05 mg/kg/day (trough 5–7 ng/mL × 52 wk, then 8-wk taper).
Outcome: Complete remission at wk 104: 37% vs 6% (adj diff 31 pp; 95% CI 18–44; P<0.001). Overall remission 51% vs 13%. Relapse: 12% vs 58% (HR 0.11). Grade ≥3 AEs 22% vs 19%; infusion reactions 38% with obinutuzumab.

Clinical takeaway: Obinutuzumab was decisively superior to tacrolimus. The editorial (Soler) notes that applying MENTOR’s remission definition, obinutuzumab’s proteinuria remission reaches 49% with faster anti-PLA2R clearance even in high-titer patients. FDA breakthrough therapy designation — potential first labeled treatment for primary MN. Extends the anti-CD20 approach from rituximab (MENTOR) to a more potent agent.

Editorial: Soler · NCT04629248

Hematology & OncologyReview · High yield · IM

Treatment Decisions in Multiple Myeloma

A practical framework for navigating the expanding myeloma treatment landscape — from induction through relapse. Key decision points:

•Quadruplet induction is standard — anti-CD38 + PI + IMiD + dex (Dara-VRd or Isa-VRd) for transplant-eligible AND fit transplant-ineligible patients (PERSEUS, GMMG-HD7, IMROZ). •ASCT may be deferred in standard-risk disease with deep MRD-negative response (IFM 2009, DETERMINATION, MIDAS showed no OS benefit). High-risk/double-hit → proceed to ASCT regardless. •Maintenance is risk-adapted: finite for standard-risk with sustained MRD negativity (MASTER, MRD2STOP); prolonged doublet for high-risk. MRD at 10⁻⁷ is a more reliable benchmark than 10⁻⁵. •At relapse: BCMA-directed CAR T (cilta-cel, CARTITUDE-4) or bispecific antibodies (teclistamab-daratumumab, MajesTEC-3) are preferred. Use CAR T cells early when T-cell fitness is preserved; switch antigen target (e.g., GPRC5D) after BCMA-directed relapse. •Functional cure emerging: cilta-cel in smoldering myeloma (CAR-PRISM) showed 100% MRD negativity — early interception may be curative in selected patients.

Clinical takeaway: The shift from triplet to quadruplet induction is now established. For inpatient oncology teams, the key practical points are: (1) quadruplet regimens are first-line for most patients, (2) ASCT timing is increasingly flexible, and (3) at first relapse, cilta-cel or teclistamab-daratumumab are the preferred options over conventional triplets. Enrollment in clinical trials should be discussed at every decision point.

RheumatologyTeaching Case · High yield · IM

Case 25-2026: A 65-Year-Old Man with Fever and Rash

In an adult with prolonged fever, palpable purpura, polyarthralgia, abdominal pain, and proteinuria after a URI, what is the unifying diagnosis?

Diagnosis: IgA vasculitis (formerly Henoch–Schönlein purpura). Classic tetrad of palpable purpura (dependent distribution), arthralgias, abdominal pain (bowel wall edema on CT), and renal involvement (hematuria, proteinuria). Diagnosed by skin biopsy showing leukocytoclastic vasculitis with granular IgA deposition on direct immunofluorescence.

•Adults vs children: adults have more systemic disease, more kidney involvement, and often require glucocorticoids. •Pitfalls: false-positive malaria RDT (always confirm with thick/thin smears); positive EBV VCA IgM in an older adult is more likely reactivation than primary infection (>90% global adult seroprevalence). •Management: glucocorticoids for organ-threatening disease; prolonged taper often needed (this patient flared with nephritis after initial steroid taper).

Toxicology / Military MedicineHigh yield · IM

Outbreak of Severe Methemoglobinemia during Maritime Migration

What caused recurrent outbreaks of life-threatening methemoglobinemia in Central Mediterranean maritime migrants?

Outbreak investigation (82 patients, Lampedusa, Italy, March 2024–December 2025). Cause: dermal absorption of N-methylaniline, a gasoline octane-boosting additive, from fuel-contaminated seawater on vessel floors. Detected in 95% of tested patients.

•Median MetHb 44.6% at presentation; 43% had levels ≥50%. Two deaths. •Treatment: IV methylene blue 1–3 mg/kg (90% of patients; 62% required multiple doses). Use even if G6PD status is unknown in severe cases. •Delayed complication: hemolytic anemia (46% of cases, onset 2–4 days) — frequently requiring transfusion. Splenic rupture in 4 patients. •Standard pulse oximetry is unreliable in methemoglobinemia — use CO-oximetry.

Military medicine relevance: Maritime interception and rescue operations may encounter mass methemoglobinemia from fuel-contaminated bilge water. Key readiness points: stock methylene blue at maritime medical facilities, obtain CO-oximetry (not just pulse ox), monitor for delayed hemolysis 2–7 days, and consider point-of-care G6PD testing.

Also in this issue

AIR-STEMI — Physiology-Guided Complete Revascularization in STEMI (Cardiology): International RCT, 1823 STEMI patients with multivessel disease. Functional coronary angiography (image-derived FFR) vs conventional angiography-guided PCI. Composite MACE 8.9% vs 13.7% (HR 0.62; P<0.001). ~49% of nonculprit lesions reclassified as not functionally significant. Lower yield for IM — interventional cardiology.
Exa-cel in Children with Beta-Thalassemia or Sickle Cell Disease (Genetics & Gene Therapy): Phase 3, open-label, single-arm study of CRISPR-Cas9 gene editing in children 5–11. All evaluable children achieved transfusion independence (TDT) or freedom from vaso-occlusive crises (SCD). One death from busulfan-related veno-occlusive disease. FDA extended age approval to ≥2 years. Lower yield for IM — pediatric gene therapy.

Anki cards this issue: 4 cards minted (cap 4–6). MAJESTY (nephrology), methemoglobinemia (toxicology), multiple myeloma review (hematology), IgA vasculitis teaching case (rheumatology). AIR-STEMI not carded (interventional cardiology). Exa-cel not carded (pediatric gene therapy). TSV attached for import.

This digest is an original paraphrase for personal study and is not affiliated with or endorsed by the New England Journal of Medicine. Full articles: NEJM Vol. 395 No. 10. DOI links above lead to the publisher’s site.